Ashton Thomas Private Wealth LLC Invests $39,000 in Agilent Technologies, Inc. (NYSE:A)

Ashton Thomas Private Wealth LLC acquired a new position in Agilent Technologies, Inc. (NYSE:A) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 298 shares of the medical research company’s stock, valued at approximately $39,000.

Other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in Agilent Technologies by 18.2% during the 1st quarter. Vanguard Group Inc. now owns 29,884,345 shares of the medical research company’s stock worth $4,348,471,000 after buying an additional 4,605,228 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Agilent Technologies by 13.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 8,542,054 shares of the medical research company’s stock worth $1,242,956,000 after buying an additional 1,042,926 shares in the last quarter. Norges Bank acquired a new stake in Agilent Technologies during the 4th quarter worth approximately $509,904,000. Van ECK Associates Corp lifted its holdings in Agilent Technologies by 0.7% during the 2nd quarter. Van ECK Associates Corp now owns 2,793,189 shares of the medical research company’s stock worth $362,081,000 after buying an additional 18,205 shares in the last quarter. Finally, Nordea Investment Management AB lifted its holdings in Agilent Technologies by 4.4% during the 1st quarter. Nordea Investment Management AB now owns 2,783,238 shares of the medical research company’s stock worth $406,715,000 after buying an additional 116,822 shares in the last quarter. 87.42% of the stock is currently owned by institutional investors and hedge funds.

Agilent Technologies Stock Up 0.7 %

Shares of NYSE:A opened at $138.31 on Tuesday. The stock has a market cap of $40.35 billion, a P/E ratio of 32.70, a P/E/G ratio of 6.43 and a beta of 1.05. The firm has a fifty day moving average price of $137.00 and a 200 day moving average price of $139.25. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.78 and a quick ratio of 1.37. Agilent Technologies, Inc. has a 1-year low of $96.80 and a 1-year high of $155.35.

Agilent Technologies (NYSE:A) last released its earnings results on Wednesday, August 21st. The medical research company reported $1.32 EPS for the quarter, topping the consensus estimate of $1.26 by $0.06. Agilent Technologies had a net margin of 21.75% and a return on equity of 25.26%. The company had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.56 billion. During the same quarter last year, the business earned $1.43 EPS. The business’s revenue was down 5.6% on a year-over-year basis. Sell-side analysts predict that Agilent Technologies, Inc. will post 5.24 EPS for the current year.

Insider Transactions at Agilent Technologies

In other news, CEO Padraig Mcdonnell sold 1,958 shares of the firm’s stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total value of $283,910.00. Following the completion of the sale, the chief executive officer now owns 24,118 shares in the company, valued at approximately $3,497,110. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.33% of the company’s stock.

Analyst Ratings Changes

A has been the topic of a number of research reports. Barclays increased their target price on shares of Agilent Technologies from $125.00 to $135.00 and gave the stock an “underweight” rating in a report on Friday, August 23rd. Evercore ISI increased their price objective on shares of Agilent Technologies from $130.00 to $135.00 and gave the company an “in-line” rating in a research report on Thursday, August 22nd. Wolfe Research downgraded shares of Agilent Technologies from an “outperform” rating to a “peer perform” rating in a research report on Thursday, June 27th. TD Cowen increased their price objective on shares of Agilent Technologies from $153.00 to $160.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Agilent Technologies from $165.00 to $155.00 and set an “overweight” rating on the stock in a research report on Thursday, May 30th. One research analyst has rated the stock with a sell rating, six have given a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $141.60.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.